A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Arthur Lui; Karen Mulder; Christine Brezden-Masley; Michael Vickers; Jose Monzon; Hagen Kennecke; Rakesh Goel; Larissa Vos; Sunita Ghosh; Horia Marginean; Anthony Fields; Jean Maroun; Jennifer Spratlin

doi:10.1007/s10637-018-0599-4

A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Investigational New Drugs ◽

10.1007/s10637-018-0599-4 ◽

2018 ◽

Vol 36 (4) ◽

pp. 674-682 ◽

Cited By ~ 1

Author(s):

Arthur Lui ◽

Karen Mulder ◽

Christine Brezden-Masley ◽

Michael Vickers ◽

Jose Monzon ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Gastroesophageal Junction ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Get full-text (via PubEx)

A multicentre, open-label phase II study of irinotecan, capecitabine, and oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.4032 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4032-4032

Author(s):

Arthur Gregory Ang Lui ◽

Karen E. Mulder ◽

Christine Brezden-Masley ◽

Michael M. Vickers ◽

Jose Gerard Monzon ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Gastroesophageal Junction ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Get full-text (via PubEx)

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study

Annals of Oncology ◽

10.1093/annonc/mdq247 ◽

2010 ◽

Vol 21 (11) ◽

pp. 2213-2219 ◽

Cited By ~ 80

Author(s):

S. Rao ◽

N. Starling ◽

D. Cunningham ◽

K. Sumpter ◽

D. Gilligan ◽

...

Keyword(s):

Gastric Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Get full-text (via PubEx)

An open-label phase II study of intermittent oral capecitabine (X) as first-line treatment for patients (pts) with metastatic colorectal cancer (MCRC)

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3730 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3730-3730

Author(s):

G. Zhongzhen ◽

F. Fengyi ◽

L. Xiaoqing ◽

W. Yajie ◽

Y. Baoming ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Oral Capecitabine ◽

Open Label Phase ◽

First Line Treatment

Get full-text (via PubEx)

Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced gastric or gastroesophageal junction (GEJ) cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.4122 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 4122-4122 ◽

Cited By ~ 5

Author(s):

M. Alsina ◽

A. H. Ko ◽

M. Garcia De Paredes ◽

F. Rivera ◽

L. S. Schwartzberg ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Gastroesophageal Junction ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Get full-text (via PubEx)

1404P Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1513 ◽

2021 ◽

Vol 32 ◽

pp. S1058

Author(s):

J. Wang ◽

T. Wu ◽

Y-G. Hong ◽

S-X. Luo ◽

N. Li ◽

...

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Phase Ii Clinical Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Get full-text (via PubEx)

Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial

Haematologica ◽

10.3324/haematol.2019.220301 ◽

2019 ◽

Vol 105 (1) ◽

pp. e29-e32 ◽

Cited By ~ 2

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Phase Ii ◽

Hemophagocytic Lymphohistiocytosis ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Non Hodgkin Lymphoma ◽

Open Label Phase ◽

First Line Treatment

Get full-text (via PubEx)

Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial

ESMO Open ◽

10.1016/j.esmoop.2021.100313 ◽

2021 ◽

Vol 6 (6) ◽

pp. 100313

Author(s):

T. Zhou ◽

Y. Yang ◽

S. Ma ◽

L. Lin ◽

T. Zhou ◽

...

Keyword(s):

Nasopharyngeal Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Metastatic Nasopharyngeal Carcinoma ◽

Open Label Phase ◽

First Line Treatment

Get full-text (via PubEx)

Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-017-3250-8 ◽

2017 ◽

Vol 79 (4) ◽

pp. 813-823 ◽

Cited By ~ 7

Author(s):

Hiroki Yamaue ◽

Atsushi Shimizu ◽

Yasuhiro Hagiwara ◽

Masayuki Sho ◽

Hiroaki Yanagimoto ◽

...

Keyword(s):

Pancreatic Cancer ◽

Oral Therapy ◽

Phase Ii Study ◽

Advanced Pancreatic Cancer ◽

Daily Regimen ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Get full-text (via PubEx)

PD07-07: Combination of Paclitaxel and Bevacizumab without or with Capecitabine as First-Line Treatment of HER2−Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): First Results from a Randomized, Multicenter, Open-Label, Phase II Study of the Dutch Breast Cancer Trialists' Group (BOOG).

10.1158/0008-5472.sabcs11-pd07-07 ◽

2011 ◽

Author(s):

SW Lam ◽

SM de Groot ◽

AH Honkoop ◽

A Jager ◽

AJ ten Tije ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Results ◽

Locally Recurrent ◽

First Line Treatment

Get full-text (via PubEx)

Capecitabine (X) plus gemcitabine (G) as first-line treatment in patients (pts) with locally advanced/metastatic pancreatic cancer: an open-label, multicenter phase II study

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.4141 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 4141-4141 ◽

Cited By ~ 1

Author(s):

H.-S. Song ◽

Y.-R. Do ◽

H.-M. Chang ◽

K.-H. Lee ◽

Y.-H. Kim ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Locally Advanced ◽

Metastatic Pancreatic Cancer ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Multicenter Phase ◽

First Line Treatment

Get full-text (via PubEx)